ProfileGDS5678 / 1442032_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 22% 25% 22% 22% 32% 26% 23% 18% 22% 23% 22% 23% 22% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5905324
GSM967853U87-EV human glioblastoma xenograft - Control 22.5095122
GSM967854U87-EV human glioblastoma xenograft - Control 32.5778925
GSM967855U87-EV human glioblastoma xenograft - Control 42.4730522
GSM967856U87-EV human glioblastoma xenograft - Control 52.4629622
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.812532
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6337626
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5261823
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4149418
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.498122
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5179323
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4909722
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5375423
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5170722